MCID: AND014
MIFTS: 41

Androgenic Alopecia

Categories: Skin diseases

Aliases & Classifications for Androgenic Alopecia

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia 12 15 33
Androgenetic Alopecia 12 72
Alopecia Androgenetica, Male Pattern Baldness 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050801
ICD10 33 L64 L64.9
UMLS 72 C0162311

Summaries for Androgenic Alopecia

Disease Ontology : 12 An alopecia that is characterized by M-shaped hair line recession and thinning of hair at the crown of the head in males.

MalaCards based summary : Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and seborrheic dermatitis. An important gene associated with Androgenic Alopecia is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Regulation of Androgen receptor activity. The drugs Fenugreek and Fenugreek seed meal have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and ovary, and related phenotype is reproductive system.

Wikipedia : 75 Pattern hair loss is hair loss that primarily affects the top and front of the scalp. In male-pattern... more...

Related Diseases for Androgenic Alopecia

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 32.5 SRD5A2 SHBG CYP19A1 AR
2 seborrheic dermatitis 30.8 SHBG LPP
3 prostatic hypertrophy 30.6 KLK3 CYP19A1 AR
4 prostate disease 30.6 KLK3 CYP19A1 AR
5 hyperandrogenism 30.5 SHBG PRL CYP19A1
6 sexual disorder 30.4 SHBG PRL KLK3
7 polycystic ovary syndrome 30.4 SHBG PRL CYP19A1
8 impotence 30.4 SHBG PRL KLK3
9 premature ovarian failure 1 30.3 SHBG PRL CYP19A1
10 ovarian disease 30.3 SHBG PRL CYP19A1
11 hair disease 30.3 LPP EDA2R
12 prostatic hyperplasia, benign 30.0 SRD5A2 SHBG KLK3 AR
13 alopecia 30.0 SHBG KRT15 HR EDA2R AR
14 gynecomastia 29.9 SHBG PRL KLK3 CYP19A1 AR
15 prostate cancer 28.3 SRD5A2 SHBG KLK3 CYP19A1 AR
16 marie unna congenital hypotrichosis 11.5
17 hypotrichosis 1 11.4
18 hypotrichosis simplex 11.4
19 47, xxy 10.6 SHBG AR
20 postmenopausal atrophic vaginitis 10.6 SHBG AR
21 nodular prostate 10.5 KLK3 AR
22 hypoactive sexual desire disorder 10.5 SHBG CYP19A1
23 sebaceous gland disease 10.5 SHBG AR
24 pelvic varices 10.5 SHBG PRL
25 gender identity disorder 10.4 CYP19A1 AR
26 transsexualism 10.4 CYP19A1 AR
27 frontal fibrosing alopecia 10.4
28 lichen planopilaris 10.4
29 rapidly involuting congenital hemangioma 10.4
30 withdrawal disorder 10.4 KLK3 AR
31 premenstrual tension 10.4 SHBG PRL
32 male reproductive organ benign neoplasm 10.4 KLK3 CYP19A1
33 cystitis cystica 10.4 KLK3 AR
34 hermaphroditism 10.4 SRD5A2 AR
35 mammographic density 10.4 PRL CYP19A1
36 diffuse alopecia areata 10.3
37 contact dermatitis 10.3
38 oligospermia 10.3 PRL AR
39 male reproductive organ cancer 10.3 SHBG KLK3 AR
40 male reproductive system disease 10.3 SHBG KLK3 AR
41 androgen insensitivity, partial 10.3 SHBG CYP19A1 AR
42 arteries, anomalies of 10.3
43 body mass index quantitative trait locus 1 10.3
44 coronary heart disease 1 10.3
45 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.3
46 hyperlipoproteinemia, type iii 10.3
47 infant gynecomastia 10.3
48 coronary artery anomaly 10.3
49 folliculitis 10.3
50 complete androgen insensitivity syndrome 10.3 SHBG CYP19A1 AR

Graphical network of the top 20 diseases related to Androgenic Alopecia:



Diseases related to Androgenic Alopecia

Symptoms & Phenotypes for Androgenic Alopecia

MGI Mouse Phenotypes related to Androgenic Alopecia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.1 AR CYP19A1 HR LPP PRL SRD5A2

Drugs & Therapeutics for Androgenic Alopecia

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Fenugreek Phase 4
2 Fenugreek seed meal Phase 4
3
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
4
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
5
Bimatoprost Approved, Investigational Phase 2 155206-00-1 5311027
6
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
7
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
8
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 54670067 5785
9
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
10 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
11 Adjuvants, Immunologic Phase 2
12 Anti-Infective Agents Phase 2
13 Protective Agents Phase 1, Phase 2
14 Radiation-Protective Agents Phase 2
15 Antiviral Agents Phase 2
16 Antioxidants Phase 1, Phase 2
17 Peripheral Nervous System Agents Phase 1, Phase 2
18 Respiratory System Agents Phase 1, Phase 2
19 Free Radical Scavengers Phase 1, Phase 2
20 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
21 Autonomic Agents Phase 1, Phase 2
22 Anti-Asthmatic Agents Phase 1, Phase 2
23 Bronchodilator Agents Phase 1, Phase 2
24 HIV Protease Inhibitors Phase 2
25
protease inhibitors Phase 2
26 Proteasome Inhibitors Phase 2
27 Androgens Phase 2
28 Cholinergic Agents Phase 2
29 abobotulinumtoxinA Phase 2
30 Acetylcholine Release Inhibitors Phase 2
31 Neurotransmitter Agents Phase 2
32 Botulinum Toxins Phase 2
33 Botulinum Toxins, Type A Phase 2
34 Ophthalmic Solutions Phase 2
35 Tranquilizing Agents Phase 2
36 Central Nervous System Depressants Phase 2
37 GABA Agents Phase 2
38 Psychotropic Drugs Phase 2
39 Anticonvulsants Phase 2
40 Antimanic Agents Phase 2
41 Immunologic Factors Phase 1, Phase 2
42 Mitogens Phase 1, Phase 2
43 Complement Factor H Phase 1, Phase 2
44 Complement System Proteins Phase 1, Phase 2
45 Immunosuppressive Agents Phase 1, Phase 2
46 Complement Inactivating Agents Phase 1, Phase 2
47
Ethanol Approved Phase 1 64-17-5 702
48
Methyltestosterone Approved Phase 1 58-18-4 6010
49
Testosterone enanthate Approved Phase 1 315-37-7 9416
50
Testosterone undecanoate Approved, Investigational Phase 1 5949-44-0

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
2 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
3 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
4 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
5 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
6 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
7 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
8 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
9 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
10 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
11 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
12 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
13 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
14 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
15 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
16 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
17 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
18 A Double-Blind, Randomized, Clinical Trial of the Efficacy and Safety Study to Compare Topical Herbal Solution and Minoxidil 5% in Healthy Male Subjects With Androgenetic Alopecia Active, not recruiting NCT03753113 Phase 3 Topical Minoxidil 5%
19 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
20 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
21 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
22 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
23 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
24 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
25 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
26 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
27 Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02150187 Phase 2
28 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
29 A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
30 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
31 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
32 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
33 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
34 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
35 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
36 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451190 Phase 2
37 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects. Completed NCT01451177 Phase 2
38 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451151 Phase 2
39 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451138 Phase 2
40 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil Completed NCT01451125 Phase 2
41 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451112 Phase 2
42 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
43 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451073 Phase 2
44 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451047 Phase 2
45 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
46 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia Completed NCT01669746 Phase 2
47 Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
48 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2
49 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
50 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma

Search NIH Clinical Center for Androgenic Alopecia

Genetic Tests for Androgenic Alopecia

Anatomical Context for Androgenic Alopecia

MalaCards organs/tissues related to Androgenic Alopecia:

41
Skin, Prostate, Ovary, Testes, Bone, Endothelial, Brain

Publications for Androgenic Alopecia

Articles related to Androgenic Alopecia:

(show top 50) (show all 1646)
# Title Authors PMID Year
1
Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. 38
30843235 2019
2
Shedding light on the FDA's 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia. 38
30252550 2019
3
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. 38
31403367 2019
4
Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. 38
30569416 2019
5
The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards the future. 38
30300013 2019
6
Erosive pustular dermatosis of the scalp: A neutrophilic folliculitis within the spectrum of neutrophilic dermatoses: A clinicopathologic study of 30 cases. 38
30617027 2019
7
Pediatric Androgenetic Alopecia: a Review. 38
31415838 2019
8
Efficacy of platelet-rich plasma in androgenetic alopecia patients. 38
30393988 2019
9
An overview of herbal alternatives in androgenetic alopecia. 38
30980598 2019
10
Androgenetic alopecia and microneedling: Every needling is not microneedling. 38
30905794 2019
11
Investigation on Microecology of Hair Root Fungi in Androgenetic Alopecia Patients. 38
31240449 2019
12
Do Kimchi and Cheonggukjang Probiotics as a Functional Food Improve Androgenetic Alopecia? A Clinical Pilot Study. 38
31385480 2019
13
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. 38
31054970 2019
14
Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and anti-androgens. 38
31400254 2019
15
Phospholipid-polymer hybrid nanoparticles mediated transfollicular delivery of Quercetin: prospective implement for the treatment of androgenic alopecia. 38
31382790 2019
16
Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. 38
30706177 2019
17
Expression of anti-aging type-XVII collagen (COL17A1/BP180) in hair follicle-associated pluripotent (HAP) stem cells during differentiation. 38
31383286 2019
18
Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. 38
31272082 2019
19
A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. 38
30566260 2019
20
Finasteride Enhances Stem Cell Signals of Human Dermal Papilla Cells. 38
31280211 2019
21
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. 38
30785992 2019
22
Long-term treatment with finasteride induces apoptosis and pathological changes in female mice. 38
30943778 2019
23
Histopathology of aging of the hair follicle. 38
30932205 2019
24
Biofibre® artificial hair implant: Retrospective study on 1,518 patients with alopecia and present role in hair surgery. 38
31168904 2019
25
Letter in response to "The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia". 38
30880717 2019
26
Generation of an integration-free human induced pluripotent stem cell line MUSIi010-A from occipital scalp fibroblasts of a male patient with androgenetic alopecia. 38
31228683 2019
27
Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. 38
30835851 2019
28
Photographic assessment improves adherence to recommended follow-up in patients with androgenetic alopecia and alopecia areata: A retrospective cohort study. 38
31062723 2019
29
Reproductive endocrinologists are the gatekeepers for male infertility care in North America: results of a North American survey on the referral patterns and characteristics of men presenting to male infertility specialists for infertility investigations. 38
31351700 2019
30
Cholesterol homeostasis: Links to hair follicle biology and hair disorders. 38
31260136 2019
31
Adipose Infiltration of the Dermis, Involving the Arrector Pili Muscle, and Dermal Displacement of Eccrine Sweat Coils: New Histologic Observations in Frontal Fibrosing Alopecia. 38
30624243 2019
32
Autologous Cellular Method Using Micrografts of Human Adipose Tissue Derived Follicle Stem Cells in Androgenic Alopecia. 38
31337037 2019
33
Platelet-Rich Plasma and Its Utilities in Alopecia: A Systematic Review. 38
31211715 2019
34
Harvested vs estimated follicular units in hair transplantation. 38
30084223 2019
35
Efficacy of Platelet-rich Plasma for Treating Androgenic Alopecia of Varying Grades. 38
31228018 2019
36
Preliminary results of the use of scalp microneedling in different types of alopecia. 38
31254437 2019
37
Fibrosing Alopecia in a Pattern Distribution (FAPD) in 16 African-Descent and Hispanic Female Patients: A Challenging Diagnosis. 38
31367598 2019
38
The diagnosis of androgenetic alopecia in children: Considerations of pathophysiological plausibility. 38
31168786 2019
39
Progressive expression of PPARGC1α is associated with hair miniaturization in androgenetic alopecia. 38
31217429 2019
40
Development of finasteride polymer microspheres for systemic application in androgenic alopecia. 38
30942390 2019
41
Relationship between androgenic alopecia and white matter hyperintensities in apparently healthy subjects. 38
31250269 2019
42
Platelet-Rich Plasma for Treating Androgenic Alopecia: A Systematic Review. 38
31187167 2019
43
Herbal Medicines For Treatment of Androgenic Alopecia. 38
31221945 2019
44
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. 38
30974011 2019
45
Correlation of Trichoscopic Findings in Androgenetic Alopecia and the Disease Severity. 38
31360040 2019
46
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. 38
31066492 2019
47
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. 38
30209896 2019
48
Prostaglandins in androgenetic alopecia in 12 men and four female. 38
30730082 2019
49
Hair distribution width - a novel trichoscopy parameter for hair miniaturization in androgenetic alopecia. 38
31066933 2019
50
A semiquantitative grading scale for frontal and vertex of androgenetic alopecia. 38
30592306 2019

Variations for Androgenic Alopecia

Expression for Androgenic Alopecia

Search GEO for disease gene expression data for Androgenic Alopecia.

Pathways for Androgenic Alopecia

GO Terms for Androgenic Alopecia

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.63 SRD5A2 EFNA3 AR
2 negative regulation of angiogenesis GO:0016525 9.5 PRL KLK3 EFNA3
3 mammary gland development GO:0030879 9.43 PRL CYP19A1
4 sex differentiation GO:0007548 9.4 SRD5A2 AR
5 androgen metabolic process GO:0008209 9.37 SRD5A2 CYP19A1
6 regulation of systemic arterial blood pressure GO:0003073 9.26 KLK3 AR
7 prostate gland growth GO:0060736 9.16 CYP19A1 AR
8 testosterone biosynthetic process GO:0061370 8.96 SRD5A2 CYP19A1
9 female genitalia development GO:0030540 8.32 CYP19A1

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.96 SHBG AR
2 androgen binding GO:0005497 8.62 SHBG AR

Sources for Androgenic Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....